American Journal of Health-System Pharmacy最新文献_第8页

Suzetrigine. Suzetrigine。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf054

引用次数: 0

Transforming professional pharmacy student education and residency training in kidney disease. 转变肾病专业药学学生教育和住院医师培训。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf047

Katherine H Cho, Katie E Cardone, Jean Moon, Calvin J Meaney

引用次数: 0

Reflections on nephrology pharmacy practice. 肾药学实践的思考。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf049

Katie E Cardone

引用次数: 0

KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. KDIGO 2024慢性肾脏疾病评估与管理临床实践指南：药师需要了解的入门知识。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf044

Linda Awdishu, Rebecca Maxson, Chelsea Gratt, Tamara Rubenzik, Marisa Battistella

{"title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.","authors":"Linda Awdishu, Rebecca Maxson, Chelsea Gratt, Tamara Rubenzik, Marisa Battistella","doi":"10.1093/ajhp/zxaf044","DOIUrl":"10.1093/ajhp/zxaf044","url":null,"abstract":"Purpose: To review the key updates in the 2024 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) and highlight the essential role of pharmacists in implementing these recommendations.Summary: The updated guideline introduces significant changes in CKD management, including the use of validated equations for estimating glomerular filtration rate (GFR) for drug dosing, with incorporation of serum cystatin C into GFR estimates for specific patient populations, and an emphasis on a comprehensive approach to delay disease progression. The guideline recommends sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for kidney disease with proteinuria, with or without diabetes, renin-angiotensin-aldosterone system inhibitors (RAASi) blood pressure control and proteinuria management, and statins to reduce the risk of atherosclerotic cardiovascular disease. New evidence supports the use of finerenone in patients with type 2 diabetes and CKD, and GLP-1 receptor agonists for their kidney-protective effects. The guidelines also emphasize the importance of nephrotoxin stewardship and prevention of acute kidney injury through patient education on sick day medication management.Conclusion: Pharmacists play a crucial role in implementing these updated guidelines through comprehensive medication management, nephrotoxin stewardship, drug dosing adjustments, and patient education. Their involvement in interprofessional care teams is essential for optimizing health outcomes in patients with CKD.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"660-671"},"PeriodicalIF":2.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pharmacist's role in transforming nephrology care. 药师在肾病护理变革中的作用。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf048

Melissa R Laub, Paul T Conway, Danuta Trzebinska, Ryan Wargo, Amanda J Condon Martinez

{"title":"The pharmacist's role in transforming nephrology care.","authors":"Melissa R Laub, Paul T Conway, Danuta Trzebinska, Ryan Wargo, Amanda J Condon Martinez","doi":"10.1093/ajhp/zxaf048","DOIUrl":"10.1093/ajhp/zxaf048","url":null,"abstract":"Purpose: To describe how pharmacists can enhance the care of individuals with chronic kidney disease by examining the role of the pharmacist in new care models.Summary: The implications of chronic kidney disease for the healthcare system, particularly for the Centers for Medicare and Medicaid Services, are profound. New payment models and the development of medications that slow progression of kidney disease are transforming the landscape of nephrology care in the US. Pharmacists can play a pivotal role as part of the interdisciplinary care team to optimize medication therapy for this population. In particular, the Kidney Care Choices value-based care model is encouraging a more holistic approach to managing kidney disease that aligns with the goals of comprehensive medication management by pharmacists. Pharmacists can leverage fee-for-service and value-based care reimbursement models in primary care and nephrology care settings to successfully implement guideline-directed medical therapy for patients with chronic kidney disease.Conclusion: The changing landscape of nephrology offers many opportunities for pharmacists to enhance patient care. More studies are needed to demonstrate the cost-effectiveness of pharmacists in this specialty to promote the expansion and impact of this role.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"672-680"},"PeriodicalIF":2.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cosibelimab. Cosibelimab。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-06-11 DOI: 10.1093/ajhp/zxaf055

引用次数: 0

It's time for more than just thoughts and prayers: A plea for a call to action. 是时候不只是思考和祈祷了：是时候呼吁采取行动了。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-05-30 DOI: 10.1093/ajhp/zxaf132

Brian W Gilbert, Rebecca F Gilbert

引用次数: 0

A student-led approach to completion of the Practice Advancement Initiative 2030 self-assessment tool with a state affiliate in North Dakota. 以学生为主导的方法，与北达科他州的州附属机构一起完成实践进步倡议2030自我评估工具。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-05-23 DOI: 10.1093/ajhp/zxae367

Madelyn J Johnson, Habiba Afifi, Amanda Meyer, Maari Loy

{"title":"A student-led approach to completion of the Practice Advancement Initiative 2030 self-assessment tool with a state affiliate in North Dakota.","authors":"Madelyn J Johnson, Habiba Afifi, Amanda Meyer, Maari Loy","doi":"10.1093/ajhp/zxae367","DOIUrl":"10.1093/ajhp/zxae367","url":null,"abstract":"Purpose: To efficiently complete Practice Advancement Initiative (PAI) 2030 self-assessments, students aimed to overcome completion barriers and collect data to identify areas for improvement with pharmacy practice in the state of North Dakota.Summary: Pharmacy departments from hospitals and health systems face challenges when completing the self-assessment tool, and creativity must be kindled to develop an appropriate approach. Over the course of a 5-week advanced pharmacy practice experience rotation, 2 students generated an efficient, personal, and novel approach to completing the PAI 2030 self-assessment tool with pharmacy leaders across the state.Conclusion: The novel student-led approach achieved a completion rate greater than the goal suggested by the American Society of Health-System Pharmacists while providing the students with learning and networking opportunities. As a result, pharmacy leaders have baseline PAI 2030 self-assessment data for 26 hospitals across North Dakota, which can be used for further analysis and application.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"e544-e550"},"PeriodicalIF":2.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Pharmacotherapy of acute ST-elevation myocardial infarction and the pharmacist's role, part 2: Complications, postrevascularization care, and quality improvement. 修正：急性st段抬高型心肌梗死的药物治疗和药师的作用，第2部分：并发症、血管化后护理和质量改进。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-05-23 DOI: 10.1093/ajhp/zxaf004

引用次数: 0

Impact of paralytic choice on postintubation sedation and analgesia in the emergency department. 麻痹选择对急诊插管后镇静镇痛的影响。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2025-05-23 DOI: 10.1093/ajhp/zxaf037

Calvin Hwang, Benjamin Michaels, Kristen Park, Andrew Dang, Christine Vo, Stephen Lee, Zlatan Coralic

{"title":"Impact of paralytic choice on postintubation sedation and analgesia in the emergency department.","authors":"Calvin Hwang, Benjamin Michaels, Kristen Park, Andrew Dang, Christine Vo, Stephen Lee, Zlatan Coralic","doi":"10.1093/ajhp/zxaf037","DOIUrl":"10.1093/ajhp/zxaf037","url":null,"abstract":"Purpose: We describe the timing of first-dose sedation and analgesia after rapid sequence intubation (RSI) in patients induced with etomidate and paralyzed with rocuronium or succinylcholine.Methods: This was a retrospective study of adult patients undergoing RSI in 3 emergency departments (EDs). We evaluated the time to administration of analgesia and sedation using a Cox proportional hazard model controlling for choice of paralytic, post-RSI hypotension (nadir systolic blood pressure of less than 100 mm Hg in the first hour), bedside presence of an ED pharmacist, and practice site. We also describe the first doses of post-RSI analgesia and sedation.Results: A total of 2,059 adult patients were included in the study, of whom 1,532 received rocuronium and 527 received succinylcholine. The median time to first dose of sedation was 12 minutes (interquartile range [IQR], 7-26 minutes) in patients given rocuronium and 10 minutes (IQR, 6-19 minutes) in those given succinylcholine. The median time to analgesia was 24 minutes (IQR, 10-78 minutes) and 21 minutes (IQR, 10-60 minutes), respectively. Administration of rocuronium was associated with lower rates of sedation (adjusted hazard ratio [aHR], 0.75; 95% confidence interval [CI], 0.67-0.85) and analgesia (aHR, 0.73; 95% CI, 0.62-0.87). Hypotension was also predictive of decreased sedation (aHR, 0.67; 95% CI, 0.54-0.80), while bedside presence of an ED pharmacist was associated with improvement (aHR, 1.14; 95% CI, 1.03-1.27). Overall, the median post-RSI initial propofol infusion rate was low at 20 μg/kg/min (IQR, 10-30 μg/kg/min).Conclusion: Use of rocuronium for RSI was associated with reduced likelihood of timely post-RSI sedation and analgesia. Coupled with low initial sedative dosing, our findings suggest that patients intubated with rocuronium are at increased risk of being awake during paralysis.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"S2929-S2936"},"PeriodicalIF":2.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0